Hence, AChE inhibitors, that is, galantamine, donepezil, and rivastigmine, have been approved as conventional pharmacotherapies for AD; these inhibitors can slow down cognitive deterioration and improve behavioral and daily living conditions in clinical usage (Giacobini 2000). Here, ACHE is linked to Alzheimer disease.